A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effects of aflibercept on the QTc
interval in cancer patients.
Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram
(ECG) parameters, clinical safety and pharmakokinetic (PK) parameters.